CalciMedica Inc
For the period ended Sep 30, 2024. Filed Nov 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 13, 2024
CALC$1.37-9.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Operating activities: | ||
| Net loss | $(9,442) | $(30,211) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 1,681 | 12,071 |
| Depreciation | 44 | 39 |
| Change in the fair value of warrant liability | (7,790) | (1,146) |
| Change in the fair value of convertible promissory notes | - | (2,022) |
| Transaction costs associated with warrants | 776 | — |
| Non-cash interest expense | - | 110 |
| Accretion of discount on short-term investment | (492) | (61) |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current and non-current assets | (705) | 2,490 |
| Accounts payable | 117 | (1,474) |
| Accrued expenses and other liabilities | (363) | (1,914) |
| Net cash used in operating activities | (16,174) | (22,118) |
| Investing activities: | ||
| Purchase of investments | (18,837) | (2,941) |
| Maturity of investments | 19,587 | 14,580 |
| Purchases of property and equipment | (6) | (78) |
| Net cash provided by investing activities | 744 | 11,561 |
| Financing activities: | ||
| Proceeds from issuance of common stock, net of issuance costs | 18,983 | 10,340 |
| Acquisition of stock of Graybug, net of cash | — | 14,859 |
| Proceeds from exercise of stock options | 20 | — |
| Merger transaction costs | — | (4,546) |
| Proceeds from issuance of common stock from ATM Facility, net of issuance costs | 49 | 72 |
| Net cash provided by financing activities | 19,052 | 20,725 |
| Net increase in cash and cash equivalents | 3,622 | 10,168 |
| Cash and cash equivalents at beginning of period | 5,530 | 1,476 |
| Cash and cash equivalents at end of period | $9,152 | $11,644 |
| Supplemental cash flow information: | ||
| Conversion of Series A, B, C-1, C-2 and D convertible preferred stock to common stock | $— | $62,071 |
| Issuance of common stock to Graybug stockholders as a result of the Merger | $— | $29,218 |
| Short-term investments assumed in the Merger | $— | $9,776 |
| Prepaid expenses and other current assets assumed in the Merger | $— | $2,096 |
| Accounts payable and accrued liabilities assumed in the Merger | $— | $2,258 |
| Conversion of C-2 warrants to common stock | $— | $442 |
| Conversion of convertible promissory notes to common stock | $— | $3,245 |
| Conversion of convertible promissory note warrants to common stock | $— | $841 |
| Financing costs included in accounts payable | $— | $297 |
| Reclassification of warrant liability to equity | $— | $216 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.